Literature DB >> 1949861

Monoclonal antibodies in imaging and therapy of colorectal cancer.

M K Lange1, E W Martin.   

Abstract

Intraoperative detection of colorectal carcinoma with the Neoprobe gamma detector has been useful in surgical decisionmaking regarding resectability by localizing additional tumor not readily identified by palpation or inspection, and in determining surgical resection margins. Tumor labeling has been achieved in 84% of the patients. Occult tumor has been identified in 18% of evaluable patients and changed operative decisions in 43% of patients. New monoclonal antibodies with radiolabels offer hope for more effective agents for imaging, Radioimmunoguided Surgery and potential therapeutic modalities.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1949861     DOI: 10.1007/bf01789208

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  61 in total

1.  The in vivo localization of anti-Wagner-osteogenic-sarcoma antibodies.

Authors:  D PRESSMAN; L KORNGOLD
Journal:  Cancer       Date:  1953-05       Impact factor: 6.860

Review 2.  Biological response modifiers: the new immunotherapy.

Authors:  K A Foon
Journal:  Cancer Res       Date:  1989-04-01       Impact factor: 12.701

3.  Monoclonal antibodies (MAb 17-1A) for the treatment of patients with metastatic colorectal carcinomas.

Authors:  H Mellstedt; J E Frödin; G Masucci; C Lindemalm; C Wedelin; B Christensson; J Shetye; P Biberfeld; A K Lefvert; P Pihlstedt
Journal:  Acta Chir Scand Suppl       Date:  1989

4.  Localization of human GW-39 tumors in hamsters by radiolabeled heterospecific antibody to carcinoembryonic antigen.

Authors:  F J Primus; R H Wang; D M Goldenberg; H J Hansen
Journal:  Cancer Res       Date:  1973-11       Impact factor: 12.701

5.  Radioimmunodetection of cancer with radioactive antibodies to carcinoembryonic antigen.

Authors:  D M Goldenberg; E E Kim; F H DeLand; S Bennett; F J Primus
Journal:  Cancer Res       Date:  1980-08       Impact factor: 12.701

Review 6.  Immunoradiotherapy for primary nonresectable hepatocellular carcinoma.

Authors:  J V Sitzmann; S E Order
Journal:  Surg Clin North Am       Date:  1989-04       Impact factor: 2.741

7.  Monoclonal antibodies in cell-mediated cytotoxicity against human melanoma and colorectal carcinoma.

Authors:  D Herlyn; M Herlyn; Z Steplewski; H Koprowski
Journal:  Eur J Immunol       Date:  1979-08       Impact factor: 5.532

8.  IgG2a monoclonal antibodies inhibit human tumor growth through interaction with effector cells.

Authors:  D Herlyn; H Koprowski
Journal:  Proc Natl Acad Sci U S A       Date:  1982-08       Impact factor: 11.205

9.  Immunoscintigraphy of colorectal carcinoma with F (ab')2 fragments of anti-CEA monoclonal antibody.

Authors:  G Buraggi; L Callegaro; A Turrin; L Gennari; E Bombardieri; G Mariani; G Deleide; M Dovis; M Gasparini; R Doci
Journal:  Cancer Detect Prev       Date:  1987

10.  Comparison of anti-fetal colonic microvillus and anti-CEA antibodies in peroperative radioimmunolocalisation of colorectal cancer.

Authors:  S D Blair; N A Theodorou; R H Begent; P M Dawson; M Salmon; S Riggs; A Kelly; G Boxer; P Southall; P Gregory
Journal:  Br J Cancer       Date:  1990-06       Impact factor: 7.640

View more
  2 in total

1.  Radioimmunolocalization of human pancreatic carcinoma xenograft by 99mTc-labeled YPC3 monoclonal antibody.

Authors:  Q Chen; S Yuan
Journal:  J Cancer Res Clin Oncol       Date:  1994       Impact factor: 4.553

2.  Combined use of preoperative 18F FDG-PET imaging and intraoperative gamma probe detection for accurate assessment of tumor recurrence in patients with colorectal cancer.

Authors:  Ismet Sarikaya; Stephen P Povoski; Osama H Al-Saif; Ergun Kocak; Mark Bloomston; Steven Marsh; Zongjian Cao; Douglas A Murrey; Jun Zhang; Nathan C Hall; Michael V Knopp; Edward W Martin
Journal:  World J Surg Oncol       Date:  2007-07-16       Impact factor: 2.754

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.